Industry: Telehealth
Telehealth startup funding
Telehealth investors now ask who pays once Medicare's temporary rules end in 2027, and what each visit earns. Our decks and models set out payer mix, margin per visit and licensing, line by line.
- Market data and named investors for virtual primary, urgent and specialty care
- Models that tie revenue to payers, visits and state licences
- Waveup prepares investor materials for telehealth and virtual care companies: $3B+ raised for 600+ startups since 2014
In short
What is telehealth startup funding?
Telehealth startup funding is the money virtual care companies raise to hire clinicians, get licensed state by state and build their platforms. It comes from angels, health and generalist VCs, rural grants and, later, growth investors or buyers. Investors check who pays first, because Medicare's home telehealth rules run only to 31 December 2027.
- Who it's for
- Virtual primary, urgent and specialty care, and telehealth platforms, pre-seed to Series D+
- What we build
- Investor deck, financial model, valuation, investor list, data room
- Prices
- Deck from $6,000, model from $3,000. Flat fees
- Track record
- $3B+ raised for 600+ startups since 2014
Market data checked on 6 November 2026. Sources are under each section.
Will telehealth continue in 2026 and beyond?
Yes, on narrower terms than in 2020. Use has settled below the pandemic peak, and Medicare's home visit rules depend on temporary extensions from Congress.
The opportunity
Video and chat visits are routine for many patients now, and new kinds of virtual clinic keep launching.
- Since January 2026, Medicare lets doctors supervise many services by live video
- AI-first primary care practices drew large venture rounds in 2026
- Rural patients still use telehealth far less than urban ones
The problem
Growth has slowed at the oldest platforms, and payment rules keep shifting. Teladoc's revenue fell 3% in Q3 2026 from a year earlier.
Market size
How many patients use telehealth, and who pays for it?
In traditional Medicare, 6.4 million people used telehealth in 2025. Four forces decide where the money goes next:
- Medicare rules: patients can get covered telehealth at home anywhere in the US through 31 December 2027
- Cash pay: Hims & Hers had 2.89 million subscribers at the end of June 2026
- Health plans and employers: Teladoc's Integrated Care had 100.1 million US members in September 2026
- Weight care: overweight and obesity ranked second among commercial telehealth diagnoses in Q2 2026
Venture capital
What kind of telehealth company raises money in 2026?
Telehealth funding hit a record in 2021, during the pandemic. In 2026, large rounds have gone to AI-first primary care and to online storefronts that sell visits, labs and prescriptions.
telehealth funding in Q2 2021, a record at the time, by CB Insights' count
raised in total by the 50 best-funded telemedicine startups, Dealroom counts
net cash Hims & Hers paid for acquisitions in the first half of 2026
Who invests in telehealth startups?
A healthtech specialist, seed funds behind AI-first and cash-pay care, an Australian VC with a telehealth exit, and a rural grant programme. More names are in our guide to healthcare venture capital firms.
Investor database
Healthtech investors in our database
The funds with the most healthtech investments. Pick a stage, or open a fund for its cheque sizes.
Top 5 by healthtech investments
Investments by industry
- Healthtech & Wellness48%
- Biotech24%
- Pharma21%
- Rounds
- Series ASeries BSeries C+
- Average cheque
- $500K–$1M$1M–$3M$3M–$10M$10M–$50M
- Based in
- New York, United States
- Invests in
- East Asia, USA
704 investments in total, 49 tagged Healthtech & Wellness.Open the full fund profile
Investments by industry
- Healthtech & Wellness42%
- Biotech26%
- Pharma18%
- Rounds
- SeedSeries ASeries BSeries C+
- Average cheque
- $100K–$500K$500K–$1M
- Based in
- Cambridge, United States
- Invests in
- Southeast Asia, USA
613 investments in total, 40 tagged Healthtech & Wellness.Open the full fund profile
Investments by industry
- Healthtech & Wellness56%
- Software & Apps12%
- AI & Deep Tech7%
- Rounds
- SeedSeries ASeries BSeries C+
- Average cheque
- $3M–$10M$10M–$50M
- Based in
- San Francisco, USA
- Invests in
- USA
83 investments in total, 38 tagged Healthtech & Wellness.Open the full fund profile
Investments by industry
- Healthtech & Wellness45%
- Biotech30%
- Pharma19%
- Rounds
- Series ASeries BSeries C+
- Average cheque
- $0–$100K$100K–$500K$500K–$1M$1M–$3M$3M–$10M
- Based in
- Menlo Park, United States
- Invests in
- Europe, USA, Canada
382 investments in total, 30 tagged Healthtech & Wellness.Open the full fund profile
Investments by industry
- Software & Apps36%
- AI & Deep Tech17%
- Healthtech & Wellness16%
- Rounds
- SeedSeries ASeries BSeries C+
- Average cheque
- $3M–$10MOver $50M$10M–$50M
- Based in
- Boston, United States
315 investments in total, 27 tagged Healthtech & Wellness.Open the full fund profile
From our investor database.
Which risks do investors price into a telehealth raise?
We asked 56 VCs for our Fundraising 2025 study why they pass. Revenue growth, unit economics, burn and missed milestones came first, then defensibility and crowded categories. Telehealth adds four questions about rules and margins.
Medicare's 2027 deadline
Medicare covers telehealth at home anywhere in the US only through 31 December 2027. After that, most patients must again be in a rural area and a medical facility.
What investors ask
- How much of your revenue rests on Medicare's temporary rules?
What your deck shows
- Revenue by payer, with Medicare telehealth on its own line
- A 2028 plan: other payers, cash pay or in-person partners
Prescribing controlled drugs
The DEA's temporary rule for prescribing controlled medicines by telemedicine runs to 31 December 2026. A special registration it proposed in January 2025 is still not final.
What investors ask
- Which patients would need an in-person visit if the DEA rule lapses?
What your deck shows
- The share of prescriptions that are controlled medicines
- An in-person route for patients who need one
Thin fees per member
Teladoc earned $1.33 a month per US Integrated Care member in Q3 2026. Access fees that small only work at very large scale.
What investors ask
- What does a patient earn you each month after clinician pay and marketing?
What your deck shows
- Contribution margin per visit or per subscriber
- Months to earn back what each patient cost to win
Drug supply and partners
In March 2026, Hims & Hers said it would stop advertising compounded GLP-1 drugs and offer Novo Nordisk's branded ones. Novo dropped its lawsuit against the company at the same time.
What investors ask
- What happens to revenue if a drug maker, pharmacy or regulator pulls a product?
What your deck shows
- Revenue by drug, pharmacy and supplier
- The approval status of every product you prescribe
How we help you raise
Flat fees agreed before we start. No success fee on advisory work.
Your care model, payer mix and plan for Medicare's 2027 deadline.
Visits, subscribers, clinician pay and licensing costs, month by month.
A range set against listed telehealth companies and recent rounds.
Health specialists, seed funds and grant programmes that fit your stage.
Licences, payer contracts, prescribing policies and privacy files, ready for review.
For a sale to a larger telehealth platform, a health plan or a provider.
Who we are
Waveup is a London-based fundraising and growth advisory, working in 60+ countries and 90+ industries. Since 2014 we have built the decks, models, CIMs and valuations behind $3B+ raised for 600+ startups. In healthtech, Waveup prepared the investor materials for Aumet's $7M pre-Series A round.
About usTelehealth startup funding FAQ
How do telehealth startups get funding?
Do VCs still invest in telehealth in 2026?
What happens to Medicare telehealth after 2027?
Is a telehealth business profitable?
Who buys telehealth companies?
How much does help with a telehealth raise cost?
Raising for a telehealth company?
Tell us your care model, who pays and the round you're planning. We'll flag the payment and prescribing questions investors will raise first.







